Xiangxue Pharmaceutical Total Liabilities
Xiangxue Pharmaceutical total liabilities. Based on the latest financial reports, Xiangxue Pharmaceutical (300147) has total liabilities worth CN¥6.89 Billion CNY (≈ $1.01 Billion USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Xiangxue Pharmaceutical's assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Xiangxue Pharmaceutical (2007–2025)
Total liabilities of Xiangxue Pharmaceutical from 2007 to 2025. This chart illustrates how Xiangxue Pharmaceutical's total liabilities have evolved over time, based on quarterly financial data. Explore Xiangxue Pharmaceutical long-term investment intensity to see how much of total assets are deployed in long-term investments.
Xiangxue Pharmaceutical Competitors by Total Liabilities
The table below lists competitors of Xiangxue Pharmaceutical ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Good Finance Securities Co Ltd
TWO:6021
|
Taiwan | NT$28.31 Billion |
|
Almendral
SN:ALMENDRAL
|
Chile | CL$3.83 Trillion |
|
Shinry Technologies Co Ltd Class A
SHE:300745
|
China | CN¥2.48 Billion |
|
Anhui Huamao Textile Co Ltd
SHE:000850
|
China | CN¥2.71 Billion |
|
Weyco Group Inc
NASDAQ:WEYS
|
USA | $56.28 Million |
|
Client Service International Inc
SHE:300663
|
China | CN¥1.47 Billion |
|
MRV Engenharia e Participações S.A
SA:MRVE3
|
Brazil | R$22.36 Billion |
|
Gladstone Commercial Corporation
NASDAQ:GOOD
|
USA | $1.09 Billion |
Liability Composition Analysis (2007–2025)
This chart breaks down Xiangxue Pharmaceutical's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Xiangxue Pharmaceutical total assets.
Liquidity & Leverage Metrics
Xiangxue Pharmaceutical Total Liabilities Ratios Explained
Xiangxue Pharmaceutical total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.24 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -10.96 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Xiangxue Pharmaceutical's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Xiangxue Pharmaceutical (2007–2025)
The table below shows the annual total liabilities of Xiangxue Pharmaceutical from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥6.70 Billion ≈ $980.59 Million |
+10.59% |
| 2024-12-31 | CN¥6.06 Billion ≈ $886.71 Million |
+1.54% |
| 2023-12-31 | CN¥5.97 Billion ≈ $873.22 Million |
-8.68% |
| 2022-12-31 | CN¥6.53 Billion ≈ $956.25 Million |
-14.27% |
| 2021-12-31 | CN¥7.62 Billion ≈ $1.12 Billion |
+37.97% |
| 2020-12-31 | CN¥5.53 Billion ≈ $808.50 Million |
+27.01% |
| 2019-12-31 | CN¥4.35 Billion ≈ $636.54 Million |
-5.71% |
| 2018-12-31 | CN¥4.61 Billion ≈ $675.08 Million |
-16.98% |
| 2017-12-31 | CN¥5.56 Billion ≈ $813.16 Million |
+29.10% |
| 2016-12-31 | CN¥4.30 Billion ≈ $629.87 Million |
+289.18% |
| 2015-12-31 | CN¥1.11 Billion ≈ $161.85 Million |
-35.59% |
| 2014-12-31 | CN¥1.72 Billion ≈ $251.26 Million |
-2.70% |
| 2013-12-31 | CN¥1.76 Billion ≈ $258.23 Million |
+24.94% |
| 2012-12-31 | CN¥1.41 Billion ≈ $206.69 Million |
+181.28% |
| 2011-12-31 | CN¥502.16 Million ≈ $73.48 Million |
+5.49% |
| 2010-12-31 | CN¥476.01 Million ≈ $69.66 Million |
+31.97% |
| 2009-12-31 | CN¥360.69 Million ≈ $52.78 Million |
+1.62% |
| 2008-12-31 | CN¥354.94 Million ≈ $51.94 Million |
-1.95% |
| 2007-12-31 | CN¥361.98 Million ≈ $52.97 Million |
-- |
About Xiangxue Pharmaceutical
Xiangxue Pharmaceutical Co.,Ltd. engages in the research and development, production, and sales of modern Chinese medicine in China. The company provides ban lan gen granules, flu-over liquid, juhong cough-off liquid, and juhong cough-off decoction; chinese herbal, such as huazhou citri grandis, goji berry, chrysanthemum, and rose dried buds; beverages, including king sarsae, asia sarsae, diet sa… Read more